Skip to main content

Table 1 Patient characteristics.

From: Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma

Median age 64.6
Male 52.8%
Stage  
I-II 46.3%
III-IV 53.7%
Primary therapy  
CEOP 17.6%
CHOP 63.0%
CHOEP 18.5%
CHOP + IMVP-16 0.9%
Radiotherapy 53.7%
Rituximab 100%
GC phenotype 33.3%
Non-GC phenotype 57.3%
B-symptoms 37.0%
LD high 64.8%
WHO > 1 19.4%
Extranodal involvement > 1 22.6%
IPI  
0-2 59.0%
3 18.1%
4-5 22.8%
  1. CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; CEOP, cyclophosphamide, epirubicin, vincristine and prednisone; CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone; IMVP, ifosfamide, mitoxantrone, eposide; LD, lactate dehydrogenase; GC, germinal center; IPI, International Prognostic Index